Marshall Wace LLP Buys Shares of 75,982 CG Oncology, Inc. (NASDAQ:CGON)

Marshall Wace LLP bought a new stake in CG Oncology, Inc. (NASDAQ:CGON) in the 2nd quarter, Holdings Channel.com reports. The fund bought 75,982 shares of the company’s stock, valued at approximately $2,399,000.

A number of other institutional investors have also modified their holdings of CGON. American International Group Inc. acquired a new stake in CG Oncology in the 1st quarter valued at about $13,443,000. TimesSquare Capital Management LLC purchased a new position in CG Oncology in the first quarter worth approximately $9,837,000. Price T Rowe Associates Inc. MD acquired a new position in CG Oncology during the 1st quarter worth approximately $43,555,000. BNP Paribas Financial Markets purchased a new stake in shares of CG Oncology in the 1st quarter valued at approximately $492,000. Finally, Vanguard Group Inc. acquired a new stake in shares of CG Oncology in the 1st quarter valued at $97,678,000. 26.56% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other CG Oncology news, Director Hong Fang Song sold 650,455 shares of CG Oncology stock in a transaction that occurred on Thursday, August 29th. The stock was sold at an average price of $35.36, for a total value of $23,000,088.80. Following the transaction, the director now directly owns 586,982 shares in the company, valued at approximately $20,755,683.52. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

CG Oncology Trading Down 1.2 %

CGON stock opened at $35.96 on Friday. CG Oncology, Inc. has a 12 month low of $25.77 and a 12 month high of $50.23. The company has a fifty day moving average price of $35.49 and a 200 day moving average price of $35.27.

CG Oncology (NASDAQ:CGON) last announced its earnings results on Thursday, August 8th. The company reported ($0.28) EPS for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.14. The business had revenue of $0.11 million during the quarter. Analysts forecast that CG Oncology, Inc. will post -1.47 EPS for the current fiscal year.

Analyst Ratings Changes

CGON has been the topic of several recent analyst reports. HC Wainwright reissued a “buy” rating and issued a $75.00 target price on shares of CG Oncology in a report on Tuesday, September 17th. Roth Mkm initiated coverage on CG Oncology in a research note on Tuesday, August 27th. They set a “buy” rating and a $65.00 target price for the company. Roth Capital raised CG Oncology to a “strong-buy” rating in a report on Tuesday, August 27th. Bank of America began coverage on shares of CG Oncology in a research report on Friday, June 28th. They set a “buy” rating and a $65.00 price objective for the company. Finally, Royal Bank of Canada assumed coverage on shares of CG Oncology in a research report on Monday, September 23rd. They issued an “outperform” rating and a $66.00 target price on the stock. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $64.43.

CG Oncology Company Profile

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.